Navigation Links
Unigene Receives 2013 Drug Delivery Partnerships Industry Achievement Award
Date:2/13/2013

"   

As the leader in the design, delivery, manufacture and development of peptide-based therapeutics, Unigene is focused on advancing its own pipeline of novel, proprietary peptide product candidates focused on metabolic disease and inflammation as well as exploiting its industry-leading Peptelligence™ platform of peptide oral drug delivery and manufacturing assets, expertise and capabilities by building a robust portfolio of strategically partnered opportunities.

"We are very proud to recognize Unigene as the DDP Innovation Award for the second year in a row," remarked Heather King , Drug Deliver Partnerships. "Without question, Unigene has secured its position as a true innovator in oral peptide delivery and, more broadly, throughout the drug development and delivery industry."

About Unigene Laboratories, Inc.

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform.  Peptelligence™ encompasses extensive intellectual property covering drug delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence.  Core Peptelligence™ assets include proprietary oral and nasal peptide drug delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements, including statements relating to Unigene's ability to build a robust portfolio of proprietary partnerships in peptide-based therapeutics based on its Peptelligence™ platform. These forward-looking statements are not guarantees of
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Unigene to Present at TIDES 2012
2. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
3. Unigenes Oral PTH Phase 2 Proof-of-Concept Data to be Presented at Upcoming Scientific Conferences
4. Unigene Provides Update Following Recent EMA Recommendation on Calcitonin-Containing Medicines
5. Unigene and Tarix Pharmaceuticals Report Highly Increased Oral Bioavailability of "Peptelligence-engineered" TXA127
6. Unigene To Present at the 2012 Obesity Societys 30th Annual Scientific Meeting
7. Unigene to Announce Third Quarter 2012 Financial Results on November 20, 2012
8. Unigene and Tarix Pharmaceuticals Enter Definitive Licensing Agreement for "Peptelligence-Engineered" TXA127
9. Unigenes Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
10. Unigene Recieves 2013 Drug Delivery Partnerships Industry Achievement Award
11. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Sept. 22, 2014 The western European ... It is largely a replacement market with fewer ... mergers, acquisitions and partnerships are redefining competitive landscape ... research service provides details about revenue forecasts, unit ... trends across the country. The changing landscape makes ...
(Date:9/22/2014)... , September 22, 2014 ... September 25   The second edition of ... are excited to announce the final nominations for the ... announced on the evening of September 25 at The Taj Mahal Palace, ... from applicants based on a variety of qualitative and ...
(Date:9/22/2014)... , Sept. 22, 2014  Elusys Therapeutics, Inc. ... treat infectious disease, today announced it has completed ... of obiltoxaximab (ETI-204). Obiltoxaximab is an anti-toxin in ... data from these studies support the safety and ... at the intended therapeutic dose. The conclusion of ...
Breaking Medicine Technology:Automated Endoscope Reprocessor Market Trends in Western Europe 2Automated Endoscope Reprocessor Market Trends in Western Europe 3Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 2Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6
... Council,joins organizations and individuals across the country and around ... December 1, 2007. Since 1988,World AIDS Day has provided ... to reinvigorate global, national, regional,and local efforts to stop ... AIDS Day is leadership. Nearly 27,years since it was ...
... Results Also Show Potentially Differentiating Pharmacokinetic ... ... Shire plc (LSE: SHP,Nasdaq: SHPGY, TSX: SHQ), the global ... results of a study,showing VYVANSE(TM) (lisdexamfetamine dimesylate), the first ...
Cached Medicine Technology:AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic 2Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration 2Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration 3Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration 4Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration 5Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration 6
(Date:9/23/2014)... driving force behind many chronic diseases, especially liver ... caused by conditions such as viral hepatitis or ... Now, scientists at Virginia Commonwealth University Massey Cancer ... preclinical studies that blocking the expression of a ... the development and progression of liver cancer by ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Becker's ... its list of "125 Hospitals and Health Systems ... health systems featured on the list have orthopedic ... earned recognition from several reputable sources. Exceptional orthopedic ... patients, front-line orthopedic research and treat professional athletes. ...
(Date:9/23/2014)... 2014 The "area under the curve of oxygen ... approach to monitoring blood oxygen levels during procedures using ... & Analgesia . , The AUC Desat provides ... lowbut also on the depth, duration, and rate of ... Paul Niklewski, PhD, of University of Cincinnati and colleagues ...
(Date:9/23/2014)... Contrary to what is often assumed about single parents, ... from The Kinsey Institute has found that single parents ... active as often as singles without children -- and ... The study, "Dating and Sexual Behavior Among Single Parents ... online in the Journal of Sex Research ...
(Date:9/23/2014)... September 23, 2014 Kenall Manufacturing, ... expanded its MedMaster™ M4 product line with a ... the M4 product line – currently available with ... – providing more flexibility when designing lighting for ... MedMaster M4 Series include:, •Three sizes available ...
Breaking Medicine News(10 mins):Health News:Study uncovers genetic driver of inflammation, uses it to prevent and treat liver cancer 2Health News:125 Hospitals With Great Orthopedic Programs 2Health News:125 Hospitals With Great Orthopedic Programs 3Health News:125 Hospitals With Great Orthopedic Programs 4Health News:125 Hospitals With Great Orthopedic Programs 5Health News:New measure provides more data on oxygen levels during sedation 2Health News:Kinsey study of single parents' dating, sexual activity contradicts assumptions 2Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 2Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 3
... don,t let love interfere with your work, researchers say , ... who found your Valentine at work, here,s good news. , ... negative effect, a new Canadian study finds. , "Most people ... they don,t affect productivity, de-motivate other colleagues or have an ...
... ... Toppers feature 100% Natural Dunlop Latex for an affordable 100% natural latex mattress or ... organic Eco Wool batting, creating an organic latex mattress, free from chemical fire-retardants. ... (PRWEB) February 14, ...
... ... practitioner now seeing patients in the River Walk Medical Arts Building. , ... (PRWEB) February 14, 2010 -- Elias Medical recently ... office is located within the River Walk Medical Arts Building at 9900 Stockdale Highway, adjacent ...
... , LOS ANGELES , ... today by Consumer Watchdog -- Anthem Blue Cross,s announcement today that ... or more should not deter the California Legislature from taking immediate ... Other California health insurers -- including Blue Shield of ...
... Feb. 13 The beauty of budding plants and ... allergy sufferers, though, gardening can be as much a chore as ... cause an onslaught of allergy symptoms, including sneezing, itchy eyes, congestion ... can take a few simple steps to minimize their risk of ...
... Compassion appeared to be contagious in experiment using volunteers ... do a good deed appears to inspire you to do ... , In an experiment, researchers recruited volunteers who watched a ... a clip from "The Oprah Winfrey Show" in which musicians ...
Cached Medicine News:Health News:Office Romance OK With Most Folks 2Health News:Foamsource Introduces Natural Slumber 100% Natural Latex Mattresses & Toppers with Free Shipping 2Health News:Foamsource Introduces Natural Slumber 100% Natural Latex Mattresses & Toppers with Free Shipping 3Health News:Elias Medical Announces Move to New Stockdale Highway Practice 2Health News:Anthem Blue Cross's Announcement That It Will Temporarily Suspend a 39% Health Insurance Rate Increase Should Not Deter Immediate Legislative Action 2Health News:Avoid Allergens to Reap the Rewards of Gardening 2Health News:Avoid Allergens to Reap the Rewards of Gardening 3Health News:Witnessing Uplifting Behavior May Spur Good Deeds 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: